The European Medicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Pertuzumab is a recombinant humanized monoclonal antibody that specifically targets the extracellular dimerization domain (subdomain II) of HER2. Based on the positive opinion from the European Medicines Agency (EMA) on March 4, 2013, a marketing authorization valid throughout the European Union (EU...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Boix-Perales, Hector, Borregaard, Jeanett, Jensen, Kristina Bech, Ersbøll, Jens, Galluzzo, Sara, Giuliani, Rosa, Ciceroni, Cinzia, Melchiorri, Daniela, Salmonson, Tomas, Bergh, Jonas, Schellens, Jan H., Pignatti, Francesco
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2014
Sujets:
Regulatory Issues: EMA
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077440/
https://ncbi.nlm.nih.gov/pubmed/24928613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0348
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires